P196 Outcome of COPD patients started on inpatient domiciliary NIV following an acute admission with hypercapnic respiratory failure
P196 Outcome of COPD patients started on inpatient domiciliary NIV following an acute admission with hypercapnic respiratory failure
Background Recurrent hypercapnic exacerbations of COPD place a significant burden on hospitals. GOLD guidelines recognise domiciliary NIV as beneficial for selected COPD patients hospitalised with acute hypercapnic respiratory failure (AHRF), especially with persistent PaCO2>7kpa. A recent study demonstrated that domiciliary NIV conferred a reduction in composite outcomes of 12-month readmission and mortality in COPD patients following hospital admission.1 Methods Data collected retrospectively for 162 admissions to the Respiratory High Dependency Unit (RHDU) with AHRF COPD exacerbations in 2017, representing 132 patients. We collected clinical information from all available hospital electronic resources. Results Mean age was 70.6 years, with a mean FEV1 of 37.4%. 24% of patients admitted were discharged with domiciliary NIV, of which 11.4% was newly initiated. Newly initiated patients (N=15) were slightly younger with more LTOT use. They had higher PaCO2 on admission and responded well to acute inpatient NIV. 73% (N=11/15) had PaCO2>7kPa at the time of NIV initiation. This group had a 12-month mortality of 40% and readmission rate of 0.7 episodes/12 months. Additional 36 patients were discharged from RHDU with persistent PaC02>7Kpa, without domiciliary NIV initiation. This group had a 12-month mortality of 30%, with readmission rates comparable with the domiciliary NIV- initiated group. However, there were deficiencies in follow-up plans with lack of repeat routine arterial blood gas (ABG) analysis for these patients compared to the NIV-initiated group. Conclusions Following an AHRF admission, COPD patients with established respiratory failure have significant mortality even at 12-months, despite inpatient domiciliary NIV initiation. However, this group may represent patients with severe illness, who may be unable to wean off NIV completely. We identified a group of patients who could have been started on domiciliary NIV as recommended by GOLD guidelines. We found low rates of follow-up ABG analysis for those who had PaCO2>7kPa during admission. We are currently developing a screening tool to ensure appropriate follow-up with repeat ABG measurements to assess potential suitability for domiciliary NIV.
Shere, C
909a9bd9-80b0-4045-87bc-9b09665bccd3
Dalton, C
a3d68bb0-87c7-4381-81ad-3c93482663e0
Oldham, J
86b6ce0f-edfa-4597-b0e2-c0e2cac96cfe
Dushianthan, A
013692a2-cf26-4278-80bd-9d8fcdb17751
12 November 2019
Shere, C
909a9bd9-80b0-4045-87bc-9b09665bccd3
Dalton, C
a3d68bb0-87c7-4381-81ad-3c93482663e0
Oldham, J
86b6ce0f-edfa-4597-b0e2-c0e2cac96cfe
Dushianthan, A
013692a2-cf26-4278-80bd-9d8fcdb17751
Shere, C, Dalton, C, Oldham, J and Dushianthan, A
(2019)
P196 Outcome of COPD patients started on inpatient domiciliary NIV following an acute admission with hypercapnic respiratory failure.
Thorax, 74 (2).
(doi:10.1136/thorax-2019-btsabstracts2019.339).
Abstract
Background Recurrent hypercapnic exacerbations of COPD place a significant burden on hospitals. GOLD guidelines recognise domiciliary NIV as beneficial for selected COPD patients hospitalised with acute hypercapnic respiratory failure (AHRF), especially with persistent PaCO2>7kpa. A recent study demonstrated that domiciliary NIV conferred a reduction in composite outcomes of 12-month readmission and mortality in COPD patients following hospital admission.1 Methods Data collected retrospectively for 162 admissions to the Respiratory High Dependency Unit (RHDU) with AHRF COPD exacerbations in 2017, representing 132 patients. We collected clinical information from all available hospital electronic resources. Results Mean age was 70.6 years, with a mean FEV1 of 37.4%. 24% of patients admitted were discharged with domiciliary NIV, of which 11.4% was newly initiated. Newly initiated patients (N=15) were slightly younger with more LTOT use. They had higher PaCO2 on admission and responded well to acute inpatient NIV. 73% (N=11/15) had PaCO2>7kPa at the time of NIV initiation. This group had a 12-month mortality of 40% and readmission rate of 0.7 episodes/12 months. Additional 36 patients were discharged from RHDU with persistent PaC02>7Kpa, without domiciliary NIV initiation. This group had a 12-month mortality of 30%, with readmission rates comparable with the domiciliary NIV- initiated group. However, there were deficiencies in follow-up plans with lack of repeat routine arterial blood gas (ABG) analysis for these patients compared to the NIV-initiated group. Conclusions Following an AHRF admission, COPD patients with established respiratory failure have significant mortality even at 12-months, despite inpatient domiciliary NIV initiation. However, this group may represent patients with severe illness, who may be unable to wean off NIV completely. We identified a group of patients who could have been started on domiciliary NIV as recommended by GOLD guidelines. We found low rates of follow-up ABG analysis for those who had PaCO2>7kPa during admission. We are currently developing a screening tool to ensure appropriate follow-up with repeat ABG measurements to assess potential suitability for domiciliary NIV.
This record has no associated files available for download.
More information
Published date: 12 November 2019
Identifiers
Local EPrints ID: 495205
URI: http://eprints.soton.ac.uk/id/eprint/495205
ISSN: 0040-6376
PURE UUID: f2610f65-dd90-46c9-b1e5-2937babeb5f3
Catalogue record
Date deposited: 01 Nov 2024 17:31
Last modified: 02 Nov 2024 02:57
Export record
Altmetrics
Contributors
Author:
C Shere
Author:
C Dalton
Author:
J Oldham
Author:
A Dushianthan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics